Volume 1.48 | Dec 17

Prostate Cell News 1.48, December 17, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe


deCODE Discovers Genetic Markers that Improve the Power of PSA Testing for Detecting Prostate Cancer 
Scientists from deCODE genetics and academic colleagues from Iceland, the UK, US, Netherlands, Spain and Romania report the discovery of a set of single-letter variations in the sequence of the human genome that impact individual baseline levels of prostate specific antigen. [Press release from deCODE Genetics discussing online prepublication in Science Translational Medicine]

Watch Procedure Now  
Use ALDEFLUOR® to Detect Prostate Precursor Cells
by STEMCELL Technologies


Interested in recruiting talented individuals? Post your career opportunities in Prostate Cell News at no cost. Contact us at [email protected]

Twitter Follow us on Twitter! @ProstateCell


Defective Cell Surface “Glue” Is Key to Tumor Invasion
The study shows that a non-adhesive form of N-cadherin, termed proNcad is present in a much higher proportion on the surfaces of the most invasive melanoma, brain tumor cells, breast cancer and prostate tumor cells, compared to less invasive tumor cells. [Press release from McGill University Health Center discussing online prepublication in Neoplasia]

UC Riverside Researchers Identify Components in Pomegranate Juice That Could Stop Cancer From Spreading
Researchers have identified components in pomegranate juice that both inhibit the movement of cancer cells and weaken their attraction to a chemical signal that promotes the metastasis of prostate cancer to the bone. [Press release from the University of California, Riverside discussing data presented at the 50th Annual Meeting of the American Society for Cell Biology]


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


The Phosphorylation of the Androgen Receptor by TFIIH Directs the Ubiquitin/Proteasome Process
In response to hormonal stimuli, a cascade of hierarchical post-translational modifications of nuclear receptors are required for the correct expression of target genes. Here, researchers show that the transcription factor TFIIH, via its cdk7 kinase, phosphorylates the androgen receptor (AR) at position AR/S515. [EMBO J]

Dual-Aptamer-Based Delivery Vehicle of Doxorubicin to Both PSMA (+) and PSMA (-) Prostate Cancers
Researchers have designed a dual-aptamer complex specific to both prostate-specific membrane antigens (+) and (-) prostate cancer cells. [Biomaterials]

Wnt/Beta-Catenin Activation Promotes Prostate Tumor Progression in a Mouse Model
Combining expression of both Wnt-signaling and Tag expression in the mouse prostate, researchers have studied the role of Wnt/beta-catenin signaling in the progression from mouse prostatic intraepithelial neoplasia to adenocarcinoma. [Oncogene]

Polymorphisms Inside MicroRNAs and MicroRNA Target Sites Predict Clinical Outcomes in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy
Researchers systematically evaluated 61 common single nucleotide polymorphisms inside miRNAs and miRNA target sites in a cohort of 601 men with advanced prostate cancer treated with androgen-deprivation therapy. [Clin Cancer Res]

Expression of Neuregulin 4 Splice Variants in Normal Human Tissues and Prostate Cancer and Their Effects on Cell Motility
The neuregulin 4 gene encodes at least five different variants (designated A1, A2, B1, B2 and B3) produced as a result of alternative splicing. Researchers have shown in a panel of prostate cancers that each form is present to differing degrees, and that principal component analysis indicates that there are three patterns of expression. The data suggest that the different forms have varied sites of expression and function, and this includes effects on cell architecture and motility. [Endocr Relat Cancer]

Mechanisms of Nitric Oxide-Mediated Inhibition of EMT in Cancer: Inhibition of the Metastasis-Inducer Snail and Induction of the Metastasis-Suppressor RKIP
Researchers show that treatment of human prostate metastatic cell lines with the nitric oxide donor, DETANONOate, inhibits epithelial to mesenchymal transition and reverses both the mesenchymal phenotype and the cell invasive properties. [Cell Cycle]

Gene Expression Profiling of the Androgen Independent Prostate Cancer Cells Demonstrates Complex Mechanisms Mediating Resistance to Docetaxel
The molecular mechanisms conferring resistance to docetaxel in prostate cancer patients remain partially understood. Researchers generated docetaxel resistant derivatives of the androgen independent prostate cancer cell lines PC-3 and DU-145. [Cancer Biol Ther]


Genetic Correction of PSA Values Using Sequence Variants Associated with PSA Levels
To search for sequence variants that associate with prostate-specific antigen (PSA) levels, researchers performed a genome-wide association study and follow-up analysis using PSA information from 15,757 Icelandic and 454 British men not diagnosed with prostate cancer. [Sci Transl Med]

Comparison of Health-Related Quality of Life 5 Years After SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial
Researchers report health-related quality of life at a mean of 5.3 years for 168 trial-eligible men who either chose or were randomly assigned to radical prostatectomy or brachytherapy following a multidisciplinary educational session. [J Clin Oncol]

Variation in Quality of Care Among Older Men With Localized Prostate Cancer
The objective of this study was to assess the racial and ethnic disparities in outcomes and their association with process-of-care measures for elderly Medicare recipients with localized prostate cancer. [Cancer]

Early Hypofractionated Salvage Radiotherapy for Postprostatectomy Biochemical Recurrence
Postprostatectomy adjuvant or salvage radiotherapy, when using standard fractionation, requires 6.5 to 8 weeks of treatment. The authors report on the safety and efficacy of an expedited radiotherapy course for salvage prostate radiotherapy. [Cancer]

Metformin and the Incidence of Prostate Cancer in Patients with Type 2 Diabetes
The objective of this study was to determine whether metformin decreases the risk of prostate cancer in patients with type 2 diabetes. [Cancer Epidemiol Biomarkers Prev]


XGEVA(TM) (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
Amgen announced top-line results from a Phase III trial evaluating XGEVA(TM) (denosumab) versus placebo in 1,432 men with castrate-resistant prostate cancer. [Amgen Press Release]

Immunovaccine Announces Preliminary Safety Results from Phase I Clinical Trial of DPX-0907 Cancer Vaccine
Immunovaccine Inc. announced preliminary safety results for its Phase I clinical trial of DPX-0907, a DepoVax™-based therapeutic cancer vaccine candidate for the treatment of patients with advanced stage breast, ovarian or prostate cancer. [Immunovaccine Inc. Press Release]

GTx Presents Results of the Capesaris(TM) (GTx-758) Phase II Proof of Concept Pharmacokinetic-Pharmacodynamic Clinical Trial
GTx, Inc. presented results of the Capesaris(TM) (GTx-758) proof of concept pharmacokinetic-pharmacodynamic (PK/PD) clinical trial at the Annual Meeting of the Society of Urologic Oncology. Capesaris is a novel oral selective estrogen receptor alpha agonist which GTx is developing for first line treatment of advanced prostate cancer. [GTx, Inc. Press Release]

EVENTS (Listed by Date)

American Association for Cancer Research (AACR) Targeting PI3K/mTOR Signaling in Cancer
February 24-27, 2011
San Francisco, United States

Cell Culture World Congress 2011 – Optimising Cell Culture Development for Biopharmaceutical, Bioprocessing and Manufacture
February 28-March 2, 2011
Munich, Germany

American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer
March 3-6, 2011
Vancouver, Canada

MENA Oncology Conference
March 11-12, 2011
Cairo, Egypt

PITTCON Conference & Expo 2011
March 13-18, 2011
Atlanta, United States

The 6th International Conference on Oncolytic Viruses as Cancer Therapeutics
March 16-19, 2011
Las Vegas, United States

United Kingdom National Stem Cell Network 2011 Annual Scientific Conference
March 30-April 1, 2011
York, United Kingdom

American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States

World Stem Cells & Regenerative Medicine Congress 2011
May 9-11, 2011
London, United Kingdom

International Society for Stem Cell Research (ISSCR) 9th Annual Meeting
June 15-18, 2011
Toronto, Canada

National Cancer Institute (NCI) Cancer Research Imaging Camp
June 19-24, 2011
St. Louis, United States

4th Annual Advances in Biodetection & Biosensors Conference and Exhibition
June 30-July 1, 2011
Hamburg, Germany

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Lab Technologist – Cell Separation (STEMCELL Technologies)

Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Prostate Cell News at no cost.
Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives  |  Events  |  Update Profile  |  Contact Us